Identification of potential key molecules and signaling pathways for psoriasis based on weighted gene co-expression network analysis

Table 2 Clinical information of healthy control individuals and patients with psoriasis in vitro validation

Group	Sample number	Sampling location	Sex	Age	Height, cm	Body weight, kg	BMI	Smoking	Drinking	History of ASCVD	History of hypertension	History of hyperlipidemia	History of diabetes	Psoriatic arthritis	Severity index, PASI	Whether to collect non-lesion parts
Normal control group	C1	Right forearm extension side	Female	47	158	54	21.6	No	No	No	No	No	No
	C2	Right sole of the foot	Male	60	178	70	22.1	Yes	Yes	No	No	No	No
	C3	Left sole of the foot	Male	59	183	81	24.2	No	No	No	No	No	No
	C4	Left armpit	Female	27	160	52	20.3	No	Yes	No	No	No	No
	C7	Left forearm extension side	Female	18	160	50	19.5	No	No	No	No	No	No
	C9	Right shoulder	Female	27	161	62	23.9	No	No	No	No	No	No
	C11	Right calf	Female	60	156	55	22.6	No	No	No	No	No	No
Psoriasis group	E2-2	Right forearm	Male	19	177	58	18.5	No	No	No	No	No	No	No	10.5	Yes
	E3-2	Back	Female	58	157	58	23.5	No	No	No	No	Yes	No	No	8	Yes
	E5-2	Left calf stretched side	Male	55	176	68	22	No	No	No	Yes	No	Yes	No	13.4	Yes
	E6-2	Outer left thigh	Female	44	166	67	24.3	No	No	No	No	No	No	No	11.9	Yes
	E7-2	Right thigh internal test	Male	62	170	66	22.8	Yes	No	No	No	No	No	No	8.6	Yes
	E8-2	Right forearm extension side	Male	48	170	58	20.1	Yes	No	No	No	No	No	No	15.4	Yes
	E10-2	Back	Male	18	172	60	20.3	Yes	No	No	No	No	No	No	22.2	Yes

ASCVD: Arteriosclerotic cardiovascular disease; BMI: Body mass index.